Results for tag: "Myotonic Dystrophy Drug"

Myotonic Dystrophy (DM) is a rare, inherited neuromuscular disorder that affects the muscles and other body systems. It is the most common form of muscular dystrophy in adults. DM is caused by a genetic mutation that affects the production of a protein called myotonin protein kinase (DMPK). Treatment for DM is focused on managing symptoms and preventing complications. Central Nervous System (CNS) drugs are used to treat a variety of neurological disorders, including DM. These drugs can help reduce muscle stiffness, improve muscle strength, and reduce fatigue. They can also help improve quality of life by reducing pain and improving mobility. Common CNS drugs used to treat DM include anticonvulsants, muscle relaxants, and antidepressants. The Myotonic Dystrophy Drug market is a rapidly growing segment of the CNS drug market. Companies in this market are focused on developing new treatments and therapies for DM. These include pharmaceutical companies, biotechnology companies, and medical device companies. Examples of companies in this market include F. Hoffmann-La Roche, Pfizer, and Novartis. Show Less Read more